These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2696029)

  • 1. Correlation of dose intensity and prognosis in adjuvant chemotherapy: an extended controversy.
    Hryniuk WM
    Recent Results Cancer Res; 1989; 115():17-24. PubMed ID: 2696029
    [No Abstract]   [Full Text] [Related]  

  • 2. Dose response for adjuvant chemotherapy of breast cancer: experimental and clinical considerations.
    Frei E
    Recent Results Cancer Res; 1989; 115():25-7. PubMed ID: 2696038
    [No Abstract]   [Full Text] [Related]  

  • 3. Dose intensity in chemotherapy of metastatic breast cancer.
    J Clin Oncol; 1985 Jun; 3(6):889-91. PubMed ID: 3891924
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravenous or oral adjuvant CMF for node-positive breast cancer.
    Lindeman GJ; Boyages J; Driessen C; Langlands AO
    Aust N Z J Surg; 1992 Jul; 62(7):556-62. PubMed ID: 1610324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolving concepts in the systemic adjuvant treatment of breast cancer.
    Bonadonna G
    Cancer Res; 1992 Apr; 52(8):2127-37. PubMed ID: 1559216
    [No Abstract]   [Full Text] [Related]  

  • 6. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
    Ost E; Illiger HJ
    Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
    [No Abstract]   [Full Text] [Related]  

  • 7. Comment on "The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival".
    Bonadonna G; Valagussa P
    Cancer Treat Rep; 1983 Jun; 67(6):527-9. PubMed ID: 6688038
    [No Abstract]   [Full Text] [Related]  

  • 8. How to improve adjuvant treatment results in postmenopausal patients.
    Mouridsen HT
    Recent Results Cancer Res; 1989; 115():144-52. PubMed ID: 2533698
    [No Abstract]   [Full Text] [Related]  

  • 9. The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival.
    Redmond C; Fisher B; Wieand HS
    Cancer Treat Rep; 1983 Jun; 67(6):519-26. PubMed ID: 6344993
    [No Abstract]   [Full Text] [Related]  

  • 10. Salvage treatments in relapsing resectable breast cancer.
    Valagussa P; Brambilla C; Zambetti M; Bonadonna G
    Recent Results Cancer Res; 1989; 115():69-76. PubMed ID: 2696043
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant chemotherapy for lymph node-negative, estrogen receptor-negative breast cancer: a tale of three trials.
    Albain KS
    J Natl Cancer Inst; 2004 Dec; 96(24):1801-4. PubMed ID: 15601631
    [No Abstract]   [Full Text] [Related]  

  • 12. [Randomized trial on the effect of radiotherapy in addition to 6 cycles CMF in node-positive breast cancer].
    Noël G; Mazeron JJ
    Cancer Radiother; 2001 Apr; 5(2):206-7. PubMed ID: 11355592
    [No Abstract]   [Full Text] [Related]  

  • 13. [Significance of cytostatic drug dose in adjuvant chemotherapy of breast carcinoma].
    Thomssen C
    Geburtshilfe Frauenheilkd; 1996 Jul; 56(7):M102-5. PubMed ID: 8964443
    [No Abstract]   [Full Text] [Related]  

  • 14. Does the addition of chemotherapy to adjuvant endocrine treatment add any benefit in ER-positive early breast cancer: can we rely on large randomized control trials in the era of personalized medicine?
    Glück S
    Ann Oncol; 2011 Sep; 22(9):1937-1938. PubMed ID: 21765047
    [No Abstract]   [Full Text] [Related]  

  • 15. [5 years' results of a CMF protocol (methotrexate, cyclophosphamide, fluorouracil) of adjuvant chemotherapy in breast cancers].
    Horner-Vallet D; Cappelaere P; Delobelle A; Depadt G; Madelain M; Demaille A
    LARC Med; 1984 Nov; 4(9):532-40. PubMed ID: 6549038
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer.
    Pronzato P; Campora E; Amoroso D; Bertelli G; Botto F; Conte PF; Sertoli MR; Rosso R
    Am J Clin Oncol; 1989 Dec; 12(6):481-5. PubMed ID: 2589228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-response effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group.
    Colleoni M; Price K; Castiglione-Gertsch M; Goldhirsch A; Coates A; Lindtner J; Collins J; Gelber RD; Thürlimann B; Rudenstam CM
    Eur J Cancer; 1998 Oct; 34(11):1693-700. PubMed ID: 9893654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy for node-negative breast cancer patients.
    Bonadonna G; Zambetti M; Valagussa P
    Recent Results Cancer Res; 1989; 115():175-9. PubMed ID: 2516350
    [No Abstract]   [Full Text] [Related]  

  • 19. Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer.
    Hryniuk WM; Figueredo A; Goodyear M
    Semin Oncol; 1987 Dec; 14(4 Suppl 4):3-11. PubMed ID: 3317849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Milan experience with adjuvant chemotherapy in premenopausal breast cancer.
    Bonadonna G; Valagussa P; Zambetti M; Brambilla C
    Recent Results Cancer Res; 1989; 115():113-7. PubMed ID: 2696023
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.